Hematology Deal Benchmarks
Benchmark deal terms across leukemia, lymphoma, myeloma, sickle cell disease, and hemophilia. Hematology deals are driven by CAR-T cell therapy licensing, gene therapy for hemoglobinopathies, and next-gen bispecifics. Benchmarks derived from 106 verified transactions.
106
Total Deals
$434M
Avg Upfront
4
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
38
license
38
acquisition
26
collaboration
4
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Kartos Therapeutics → Ipsen navtemadlin | acquisition | $450M | $1.8B | Aug 2026 |
Zealand Pharma → Royalty Pharma rusfertide (PTG-300) | license | $50M | $100M | Aug 2026 |
Silence Therapeutics → Hansoh Pharmaceutical mRNAi GOLD platform (siRNA therapies, 3 targets) | option | $16M | — | Jun 2026 |
Vega Therapeutics (Star Therapeutics) → Incyte Late-stage von Willebrand disease drug | acquisition | $1.3B | $2.0B | Jun 2026 |
Vega Therapeutics → Incyte VGA039 (Protein S modulator) | acquisition | $1.3B | $2.0B | Jun 2026 |
Agios Pharmaceuticals → Vulcan Experimental blood-disorder drug | license | $10M | $165M | Jun 2026 |
Jiangsu Hengrui Pharmaceuticals → Bristol Myers Squibb Portfolio of 13 early-stage programs (oncology, hematology, immunology) | collaboration | $600M | $15.2B | May 2026 |
Protagonist Therapeutics → Takeda rusfertide | license | $475M | — | Apr 2026 |
TJ Bio → Biogen Felzartamab | license | $100M | $850M | Apr 2026 |
Chia Tai Tianqing Pharmaceutical Group → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Benchmark Your Hematology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 106 verified hematology transactions.
Hematology Deal Benchmarking FAQ
How are CAR-T cell therapy deals structured in 2026?
CAR-T deals have evolved beyond the initial licensing wave to feature more sophisticated structures. Allogeneic (off-the-shelf) CAR-T deals command premium upfronts ($100M-$400M+) given the manufacturing scalability advantage. Autologous CAR-T deals are increasingly structured as co-development or profit-sharing arrangements, with royalties of 15-25% for licensed products.
What deal terms are typical for sickle cell gene therapy?
Sickle cell gene therapy deals are among the highest-valued in hematology, reflecting the curative potential and large addressable population. Following the approval of gene therapies for SCD, next-gen approaches (in vivo gene editing, non-viral delivery) are seeing upfronts of $100M-$300M+ with total deal values exceeding $2B.
How do bispecific antibody hematology deals compare to solid tumor deals?
Hematology bispecific deals typically feature higher upfronts than solid tumor bispecifics due to the validated mechanism (following blinatumomab and teclistamab approvals). CD20xCD3, BCMAxCD3, and novel target combinations see upfronts of $75M-$250M, with royalties of 12-20%. The competitive landscape is more defined, allowing more confident valuation benchmarking.